CRISPR Therapeutics AG (CRSP) Other Operating Expenses (2016 - 2026)

CRISPR Therapeutics AG (CRSP) has 9 years of Other Operating Expenses data on file, last reported at $45.9 million in Q1 2026.

• For the quarter ending Q1 2026, Other Operating Expenses fell 20.1% year-over-year to $45.9 million; the trailing twelve-month figure through Mar 2026 stood at $368.7 million (up 181.0% YoY), and the FY2025 full-year result was $309.7 million, up 156.68% from the prior year.
• Other Operating Expenses declined to $45.9 million in Q1 2026, from $124.2 million in the prior quarter.
• In the past five years, Other Operating Expenses ranged from a high of $141.4 million in Q2 2025 to a low of $6.8 million in Q4 2022.
• A 5-year average of $46.3 million and a median of $42.2 million in 2023 frame the typical range for Other Operating Expenses.
• Across the five-year window, Other Operating Expenses slumped 78.56% in 2022 and soared 1092.56% in 2025, its largest moves.
• Tracing CRSP's Other Operating Expenses over 5 years: stood at $6.8 million in 2022, then surged by 193.13% to $20.0 million in 2023, then tumbled by 47.92% to $10.4 million in 2024, then soared by 1092.56% to $124.2 million in 2025, then slumped by 63.01% to $45.9 million in 2026.
• Business Quant data shows CRSP's Other Operating Expenses at $45.9 million in Q1 2026, $124.2 million in Q4 2025, and $57.1 million in Q3 2025.